Literature DB >> 11800644

Expression of E-cadherin and p53 proteins in human soft tissue sarcomas.

Jinyoung Yoo1, Sonya Park, Chang Suk Kang, Seok Jin Kang, Byung Kee Kim.   

Abstract

OBJECTIVE: To investigate the expression of E-cadherin in human soft tissue sarcomas and its potential relationship to p53 alterations.
DESIGN: Tissue sections of 91 soft tissue sarcomas were analyzed by immunohistochemistry for E-cadherin and p53 proteins. Sixty-one tumors were investigated further by the application of the polymerase chain reaction technique and a direct sequence analysis procedure of exons 5 through 8 in the p53 gene.
SETTING: Tertiary-care teaching hospital. PATIENTS: Ninety-one patients with soft tissue tumor were treated surgically. Thirteen of these patients had tumors with epithelial differentiation.
RESULTS: E-Cadherin was expressed at the cell-cell boundaries in 11 samples (12%): 9/13 (69%) with and 2/78 (3%) without histologic evidence of epithelial elements. Other sarcomas were completely negative for E-cadherin. Overexpression of p53 was detected in 30 cases (33%), 7 of which also demonstrated mutations in the p53 gene. The frequencies of p53 abnormalities in tumors with and without epithelial components were 8% and 37%, respectively. No association was established between E-cadherin immunoreactivity and p53 abnormalities (P =.13). Tumor grade strongly correlated with p53 alterations (P =.01), but not with E-cadherin expression (P =.07).
CONCLUSIONS: These data support the involvement of p53 alterations in the pathogenesis of soft tissue sarcomas. The lack of E-cadherin expression in these tumors, with the exception of lesions showing epithelial differentiation, indicates that E-cadherin is not an important factor involved in cell-cell adhesion in sarcomas. It is, however, suggested that E-cadherin may play a role in the development and/or maintenance of epithelial architecture in sarcomas, regardless of p53 status.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11800644     DOI: 10.5858/2002-126-0033-EOECAP

Source DB:  PubMed          Journal:  Arch Pathol Lab Med        ISSN: 0003-9985            Impact factor:   5.534


  6 in total

1.  E-cadherin expression in transitional cell carcinomas.

Authors:  Eszter Székely; Virág Török; Tamás Székely; Péter Riesz; Imre Romics
Journal:  Pathol Oncol Res       Date:  2006-06-24       Impact factor: 3.201

2.  Expression of E-cadherin, beta-catenin and topoisomerase IIalpha in leiomyosarcomas.

Authors:  Pinelopi N Gogou; Anna Batistatou; Emilios E Pakos; Nikiforos Apostolikas; Dimitrios Stefanou; Pericles G Tsekeris
Journal:  Clin Transl Oncol       Date:  2009-08       Impact factor: 3.405

3.  Clinicopathologic study of E-cadherin/beta-catenin complex, and topoisomerase-II in a series of 71 liposarcoma cases.

Authors:  Pinelopi Gogou; Emilios Pakos; Anna Batistatou; Ioannis Panelos; Evangelos Briasoulis; Dimitrios Stefanou; Nikoforos Apostolikas; Periclis Tsekeris
Journal:  World J Surg Oncol       Date:  2012-02-02       Impact factor: 2.754

4.  Down-regulated E-cadherin expression is associated with poor five-year overall survival in bone and soft tissue sarcoma: results of a meta-analysis.

Authors:  Ning Wang; Yong-Lai He; Li-Juan Pang; Hong Zou; Chun-Xia Liu; Jin Zhao; Jian-Ming Hu; Wen-Jie Zhang; Yan Qi; Feng Li
Journal:  PLoS One       Date:  2015-03-30       Impact factor: 3.240

5.  Distinct subcellular localization of E-cadherin between epithelioid angiomyolipoma and triphasic angiomyolipoma: A preliminary case-control study.

Authors:  Xin-Gang Bi; Lei Guo; Xiao-Liang Wang; Qian Wei; Qiang Du; Wen-Hao Jiang; Guang-Yuan Zheng; Hong-Tu Zhang; Jian-Hui Ma; Shan Zheng
Journal:  Oncol Lett       Date:  2017-05-29       Impact factor: 2.967

6.  Depletion of Langerhans cells in human papillomavirus type 16-infected skin is associated with E6-mediated down regulation of E-cadherin.

Authors:  Kate Matthews; Cheng Mee Leong; Lindsay Baxter; Emma Inglis; Kankatsu Yun; B Thomas Bäckström; John Doorbar; Merilyn Hibma
Journal:  J Virol       Date:  2003-08       Impact factor: 5.103

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.